Focused On-demand Library for Succinate dehydrogenase cytochrome b560 subunit, mitochondrial

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.







Alternative names:

Integral membrane protein CII-3; QPs-1; Succinate dehydrogenase complex subunit C; Succinate-ubiquinone oxidoreductase cytochrome B large subunit

Alternative UPACC:

Q99643; O75609; Q3C259; Q3C2D8; Q3C2H4; Q5VTH3


The Succinate dehydrogenase cytochrome b560 subunit, mitochondrial, known alternatively as Integral membrane protein CII-3, QPs-1, Succinate dehydrogenase complex subunit C, and Succinate-ubiquinone oxidoreductase cytochrome B large subunit, plays a pivotal role in the mitochondrial electron transport chain. It is crucial for transferring electrons from succinate to ubiquinone, facilitating cellular energy production.

Therapeutic significance:

Linked to Paragangliomas 3 and Paraganglioma and gastric stromal sarcoma, this protein's genetic variants underscore its importance in disease pathogenesis. Understanding its role could lead to novel therapeutic strategies targeting these conditions, emphasizing the need for further research into its biological mechanisms and potential as a therapeutic target.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.